Benjamin M. Solomon
Expertise in
69
conditions

Dr. Benjamin M. Solomon

Oncology
1000 E 23rd St Suites 230 & 320, 
Sioux Falls, SD 
Offers Telehealth
Expertise in
69
conditions
1000 E 23rd St Suites 230 & 320, 
Sioux Falls, SD 

Overview

Benjamin M. Solomon, MD, is an expert in medical oncology at Avera Medical Group Oncology & Hematology in Sioux Falls, SD.

Dr. Solomon is highly rated in 69 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Neuroendocrine Tumor, Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Dr. Solomon is board certified in American Board Of Internal Medicine Certifications: Internal Medicine Hematology Medical Oncology. He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 35 clinical trials.

Graduate Institution

University Of Nebraska Medical Center, Omaha NE, Medical School

Residency

Mayo School of Graduate Medical Education, Rochester, MN, Internal Medicine

Specialties

Oncology

Licenses

Internal Medicine in SD

Board Certifications

American Board Of Internal Medicine Certifications: Internal Medicine Hematology Medical Oncology

Fellowships

Mayo School of Graduate Medical Education, Rochester, MN, Hematology and Oncology

Hospital Affiliations

Avera St Mary's Hospital
Avera Marshall Regional Medical Ctr
Avera Queen Of Peace
Brookings Health System
Avera Mckennan Hospital & University Health Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 9 Less Insurance Carriers -

Locations

Avera Medical Group Oncology & Hematology — Prairie Center
1000 E 23rd St Suites 230 & 320, Sioux Falls, SD 57105
Other Locations
Avera Infusion — Brookings
310 22nd Ave, Suite 101, Brookings, SD 57006
Avera Cancer Institute — Sioux Falls
1000 E 23rd St, Suite 340, Sioux Falls, SD 57105

Additional Areas of Focus

Dr. Solomon has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

35 Clinical Trials

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: April 13, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
View 9 Less Clinical Trials

4 Total Publications

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Journal: Genome medicine
Published: January 22, 2021
Similar Doctors
Expertise in
16
conditions
Dr. David Starks
Oncology
Expertise in
16
conditions
Dr. David Starks
Oncology
Referral may be required

Avera Medical Group Gynecologic Oncology — Prairie Center

1000 E 23rd St, Suite 350, 
Sioux Falls, SD 
 (0.1 miles away)
605-322-7535
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. David Starks is a gynecologic oncologist at Avera Medical Group Gynecologic Oncologist. Dr. Starks is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Ovarian Cancer, Oophorectomy, and Hysterectomy.

Expertise in
53
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Expertise in
53
conditions
Dr. Vinod Parameswaran
Hematology | Oncology
Referral may be required

Avera Medical Group Hematology

1000 E 23rd St Ste 200, 
Sioux Falls, SD 
 (1.4 miles away)
605-322-3035
Languages Spoken:
English
See accepted insurances

Vinod Parameswaran is a Hematologist and an Oncologist practicing medicine in Sioux Falls, South Dakota. Dr. Parameswaran is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, Diencephalic Syndrome, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
16
conditions
Dr. Luis A. Rojas
Oncology
Expertise in
16
conditions
Dr. Luis A. Rojas
Oncology
Referral may be required

Avera Medical Group Gynecologic Oncology — Prairie Center

1000 E 23rd St, Suite 350, 
Sioux Falls, SD 
 (0.1 miles away)
605-322-7535
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luis A. Rojas, MD, provides gynecologic oncology services at Avera Medical Group Gynecologic Oncology in Sioux Falls, SD. Dr. Rojas is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, Hysterectomy, and Oophorectomy. Dr. Rojas is board certified in American Board Of Obstetrics And Gynecology; Board Certified In Gynecologic Oncology.

Frequently Asked Questions about Dr. Benjamin M. Solomon

How do I make an appointment with Dr. Benjamin M. Solomon?

You can book an appointment with Dr. Benjamin M. Solomon by calling their office at 605-322-6900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Benjamin M. Solomon a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Benjamin M. Solomon is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Benjamin M. Solomon specialize in?

While Dr. Benjamin M. Solomon is a Oncology, they have specific expertise in Lung Cancer, Neuroendocrine Tumor, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Benjamin M. Solomon participate in research or clinical trials?

Yes. Dr. Benjamin M. Solomon has published 4 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Benjamin M. Solomon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Benjamin M. Solomon accept my insurance?

Dr. Benjamin M. Solomon accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 605-322-6900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Solomon's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 49 Advanced Conditions
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile